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Bleeding ComplicationsTo the Editor: The percutaneous renal biopsy is an
essential tool in the diagnosis and evaluation of kidney
disease. Most renal biopsies are performed under direct
ultrasound guidance with automated biopsy needles,
techniques that have substantially reduced the risks of
the procedure.1–3 However, the kidney biopsy still
carries a considerable risk of bleeding complications.
Although certain risk factors for bleeding, including
hypertension, acute kidney injury, female sex, and older
age, have been well documented,4 the association
between the biopsy needle size and the rate of bleeding
complications is unclear. Major complications, including
hemorrhage requiring transfusion, angiographic inter-
vention, nephrectomy, or death, have been reported in
only around 2%–8% of renal biopsies, whereas minor
complications, such as hematoma, are seen in anywhere
from 17% to 33%.4,5 Hematoma formation found on
renal ultrasound is a direct assessment of post-biopsy
bleeding and may be a more sensitive measure of
bleeding than overt anemia or hemodynamic instability.
At our institution, post-biopsy ultrasounds are routinely
obtained as standard of care after kidney biopsy. We
therefore conducted a retrospective cohort study of
patients who underwent kidney biopsy, using post-
biopsy hematoma as the endpoint of interest when
comparing 14G versus 16G needles.
The study was conducted at Brigham and Women’s
Hospital in Boston, MA, between August 2014 and
January 2016. We captured all biopsies that were
performed under the supervision of a single
nephrology attending, allowing for minimal variation
in how procedures in our cohort were supervised and
performed. The biopsies captured comprise the large
majority of the ultrasound-guided renal biopsies con-
ducted during the period of the study.
During the period of the study, the standard of
care switched from the use of 14G to 16G needles,
based on anecdotal observations of excessive numbers324of hematomas noted in the 14G group. Spring-loaded,
automated needles were used for all biopsies. All bi-
opsies were conducted by or under the supervision of
the same nephrology attending, and all patients were
monitored for at least 6 hours after biopsy. A renal
pathologist conﬁrmed the adequacy of the sample at
the time of the biopsy. The presence of a hematoma was
ascertained by immediate post-biopsy ultrasound. We
used electronic health record databases to capture de-
mographic and clinical data. The outcome of interest
was the occurrence of a post-biopsy hematoma. The
secondary outcome was the change in hemoglobin
concentration before and 6 hours after biopsy.
We used a c2 or t-test to compare baseline charac-
teristics between patients with 16G and 14G needles.
We used multivariate logistic regression to test the
association between the needle size and the occurrence
of a post-biopsy hematoma adjusted for clinical and
demographic characteristics. We selected covariates
that were previously shown to be associated with an
increased risk of bleeding after biopsy including age,
sex, needle size, platelet count, systolic blood pressure,
and estimated glomerular ﬁltration rate. We addition-
ally adjusted for fellow performance of biopsies and the
number of passes. Finally, we adjusted for the presence
of >40% ﬁbrosis on the biopsy as this was associated
with a risk of hematoma in the univariate analysis. We
used R, version 3.2.2, for all statistical analyses and
considered P < 0.05 to be statistically signiﬁcant.
Our cohort consisted of 86 patients with a mean age
of 56.5  16.9 years. Baseline characteristics, stratiﬁed
by needle size and by the occurrence of a hematoma,
are shown in Table 1. A 14G biopsy needle was used in
44 (51%) of patients and a 16G biopsy needle was used
in the remaining patients. There were a similar pro-
portion of patients who had inpatient biopsies in the
14G group compared with the 16G group (34% vs.
43%, respectively, P ¼ 0.54). More passes were per-
formed to obtain adequate samples in the 14G group
compared with the 16G group (2.7 vs. 2.2, respectively,
P ¼ 0.003). There was no effect of the number of passes
on the risk of hematoma (P ¼ 0.49).
Hematoma formation was more frequent among in-
dividuals who underwent kidney biopsy using 14G
needles compared with 16G needles (41% vs. 17%,
respectively, P ¼ 0.03). There was no difference in
the diagnostic yield of glomeruli between the 2 groups
(43  21.6 vs. 37  12.3 glomeruli, respectively,
P ¼ 0.13). There were no patients in whom the tissue
obtained was inadequate to make a diagnosis. In a
logistic regression analysis, the use of a 14G needle
was associated with a signiﬁcantly higher risk of he-
matoma (odds ratio 5.72, 95% conﬁdence interval
1.54–25.7, P ¼ 0.01) after multivariable adjustment forKidney International Reports (2016) 1, 321–326
Table 2. Predictors of hematoma after renal biopsy
Predictor
Univariate model Multivariate model
Odds
ratio 95% CI
P-
value
Odds
ratio 95% CI
P-
value
14-gauge versus 16-gauge 3.46 1.30–10.0 0.02 5.72 1.54–25.7 0.01
Left versus right side 2.03 0.65–7.71 0.25 2.05 0.48–10.4 0.35
Number of passes 1.24 0.67–2.25 0.48 0.99 0.42–2.28 0.98
Platelets (per 100 K/ml) 1.60 1.02–2.68 0.054 1.91 1.06–3.87 0.05
Interstitial ﬁbrosis >40%
versus <40%
4.70 1.76–13.1 0.002 5.86 1.53–25.6 0.01
Age (per 10 yr) 0.85 0.65–1.12 0.25 0.83 0.55–1.22 0.35
Female versus male 0.95 0.37–2.43 0.9 0.58 0.17–1.87 0.37
Factors adjusted for in the multivariate model: age, gender, needle size, whether fellow
performed the biopsy, kidney that was biopsied, number of passes, platelet count,
systolic blood pressure, eGFR, interstitial ﬁbrosis (>40% vs. <40%).
CI, conﬁdence interval; eGFR, estimated glomerular ﬁltration rate.
Table 1. Baseline characteristics of the participants—16-gauge versus 14-gauge biopsy needle size; with and without hematoma
16-gauge 14-gauge P-value With hematoma Without hematoma P-value
Demographics
Age, mean (SD) 59.7  15.1 53.18  18.2 0.07 53.0  17.6 57.7  16.7 0.26
Female, n (%) 19 (45.2%) 23 (52.3%) 0.7 12 (48.0%) 30 (49.2%) 1.0
Lab values
INR, median IQR 1 (0.95, 1.05) 1 (0.99, 1.01) 0.15 1 (1, 1) 1 (0.95, 1.05) 0.26
PTT, s (SD) 30.81  6.5 30.01  5.3 0.54 30.13  5.2 30.51  6.2 0.77
Pre-Hb, g/dl (SD) 11.33  2.1 11.27  2.0 0.88 11.23  1.8 11.32  2.1 0.84
Platelets, K/ml (SD) 273  133.7 239.32  69.5 0.15 293.24  133.8 240.41  90.0 0.07
Creatinine, mg/dl (SD) 3.04  7.5 2.13  1.8 0.45 2.12  1.3 2.76  6.4 0.46
Proteinuria, mg albumin/g creatinine (SD) 2937.62  5942.6 2453.54  2958.4 0.67 3945.07  8182.8 2279.08  2651.2 0.68
eGFR, ml/min per 1.73 m2 (SD) 44.30  27.0 51.00  37.6 0.34 43.2  32.4 49.6  33.2 0.42
eGFR < 30, n (%) 14 (31.8%) 14 (66.7%) 0.003 11 (44%) 17 (72.1%) 0.03
BMI (SD) 27.24  4.7 26.98  5.08 0.42 26.70  5.6 27.27  4.6 0.68
Biopsy characteristics
Left side, n (%) 34 (80.9%) 31 (70.5%) 0.38 21 (84%) 44 (72%) 0.38
Passes, n (SD) 2.19  0.59 2.66  0.83 0.003 2.52  0.77 2.39  0.76 0.49
Systolic blood pressure, mm Hg (SD) 134.38  16.7 130.95  16.8 0.35 133.20  18.9 132.39  15.9 0.85
Diastolic blood pressure, mm Hg (SD) 73.31  10.9 71.45  13.5 0.48 74.76  12.3 71.38  12.2 0.25
Fellow, n (%) 18 (42.9%) 28 (63.6%) 0.09 15 (60%) 31 (50.8%) 0.59
Inpatient biopsy, n (%) 18 (42.9%) 15 (34.1%) 0.54 8 (32%) 25 (41.0%) 0.59
Post Hb, g/dl (SD) 10.89  2.0 10.67  1.9 0.60 10.44  1.7 10.92  2.0 0.27
Hb drop, g/dl (SD) 0.44  0.7 0.59  0.7 0.31 0.80  0.68 0.40  0.69 0.02
Hb drop > 1 g/dl (SD) 8 (19.0%) 10 (22.7%) 0.88 9 (36%) 9 (14.8%) 0.06
Hematoma, n (%) 7 (16.7%) 18 (40.9%) 0.03 N/A N/A N/A
Pathology
Glomeruli, mean (SD) 37.43  12.3 43.23  21.6 0.13 40.80  20.3 40.23  16.9 0.90
Interstitial ﬁbrosis, % (SD) 31.67  21.0 28.75  21.9 0.53 40  22.5 26.1  19.7 0.01
Interstitial ﬁbrosis >40%, n (%) 13 (31.0%) 14 (31.8%) 0.9 14 (56%) 13 (21.3%) 0.004
BMI, body mass index; eGFR, estimated glomerular ﬁltration rate; INR, international normalized ratio; IQR, interquartile range; PPT, partial thromboplastin time.
RESEARCH LETTERScommonly reported factors associated with post-
biopsy complications, including age, gender, needle
size, whether a fellow performed the biopsy, the
kidney that was biopsied, number of passes, systolic
blood pressure, and eGFR (Table 2). Other factors that
were signiﬁcantly associated with hematoma in the
multivariable model included the platelet count and
the presence of signiﬁcant (>40%) ﬁbrosis on the renal
biopsy. The post-biopsy fall in hemoglobin levels was
0.4 g/dl greater in patients who had a post-biopsy
hematoma (P ¼ 0.03). Two patients experienced a
major complication: one requiring angiographic
intervention and the other requiring a urinary stent,
both in the 14G group. Among individuals who un-
derwent outpatient biopsy, one patient in the 16G
group was admitted for observation because of biopsy-
related issues, compared with 6 patients admitted in
the 14G group (P ¼ 0.12).
The use of 14G needles was associated with a higher
complication rate without providing any appreciable
beneﬁt for diagnostic yield. Although the presence of
a hematoma is a minor complication, it is associated
with an increased risk of major complications. One
study has shown that the absence of a hematoma 1 hour
after biopsy was strongly associated with an uncom-
plicated post-biopsy course, although the presence of aKidney International Reports (2016) 1, 321–326hematoma at 1 hour after biopsy was not predictive of a
complicated post-biopsy course (positive predictive
value of 43% and negative predictive value of 95% for
predicting clinical complications).6 Another study
found that the presence of a perirenal hematoma >2 cm
immediately after biopsy was the strongest predictor of
more severe anemia the morning after biopsy.7 The
occurrence of a hematoma can also lead to longer hos-
pital stays and higher treatment costs. We have pre-
viously shown that in our institution, outpatient
biopsies are associated with an 82% decrease in costs325
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RESEARCH LETTERSrelative to inpatient biopsies.8 Although not statisti-
cally signiﬁcant, there was a reduction in the number
of admissions for observation in our cohort using 16G
needles that, based on our prior research, likely
reduced overall costs associated with the procedure.
Whether or not larger needles are associated with a
higher complication rate after kidney biopsy is
controversial. Smaller studies have found no associa-
tion between needle size and major complications.5,8,9
This may be due in part to the low overall event rate
of major complications in these studies. In contrast, a
large meta-analysis of biopsies from 1980 to 2011
found that the use of 14G needles was associated with
a higher rate of transfusion after biopsy compared
with 16G and 18G needles.4 However, another large
study using data from a Norwegian kidney biopsy
registry spanning a similar time frame found that
there was no difference in major complication rates
between 14G and 16G needles,10 although the overall
rate of complications in that study was remarkably
low. In addition, there was a trend towards a higher
rate of complications in individuals using 18G nee-
dles, suggesting that there may have been a selection
bias where patients perceived to be at a higher risk of
bleeding were more likely to have a biopsy with
smaller needles. More recently, a study comparing
14G and 16G needles found that there was no differ-
ence in adequacy but that the rate of post-biopsy
hematoma was signiﬁcantly higher with larger nee-
dles (39% vs. 22%).11 These ﬁndings were compara-
ble to the results of this study.
The ﬁndings of this study are limited due to the
small sample size and its retrospective nature, which
could introduce potential bias. Our ﬁndings suggest
that there is a need to carefully weigh the potential
risks of using a larger biopsy needle against the desire
for more diagnostic tissue.
In conclusion, 16G needles result in fewer post-
biopsy hematomas and have equivalent diagnostic
yield compared with 14G needles for kidney biopsy.
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